Bluefin Capital Management’s Gilead Sciences GILD Stock Holding History

Bluefin Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,900	Closed	-$970K	–	154
2025 Q4	$970K	Buy	+7,900	New	+$960K	0.24%	52
2024 Q1	–	Sell	-12,700	Closed	-$1.03M	–	202
2023 Q4	$1.03M	Buy	+12,700	New	+$988K	0.09%	47
2023 Q1	–	Sell	-46,568	Closed	-$4M	–	332
2022 Q4	$4M	Buy	46,568 +38,568	+482%	+$3.05M	0.59%	31
2022 Q3	$494K	Buy	8,000 +2,900	+57%	+$183K	0.04%	190
2022 Q2	$319K	Sell	5,100 -9,100	-64%	-$563K	0.04%	226
2022 Q1	$844K	Buy	14,200 +1,500	+12%	+$95.9K	0.08%	150
2021 Q4	$922K	Sell	12,700 -45,460	-78%	-$3.13M	0.06%	239
2021 Q3	$4.06M	Buy	58,160 +18,180	+45%	+$1.28M	0.4%	46
2021 Q2	$2.75M	Buy	39,980 +16,380	+69%	+$1.09M	0.18%	93
2021 Q1	$1.52M	Buy	23,600 +20,012	+558%	+$1.29M	0.07%	137
2020 Q4	$209K	Buy	+3,588	New	+$217K	0.01%	429
2020 Q3	–	Sell	-6,090	Closed	-$422K	–	234
2020 Q2	$469K	Buy	6,090 +2,290	+60%	+$175K	0.04%	157
2020 Q1	$284K	Sell	3,800 -64,189	-94%	-$4.44M	0.04%	220
2019 Q4	$4.42M	Buy	67,989 +57,604	+555%	+$3.75M	0.29%	90
2019 Q3	$658K	Buy	+10,385	New	+$679K	0.1%	153
2019 Q2	–	Sell	-4,140	Closed	-$269K	–	393
2019 Q1	$269K	Buy	+4,140	New	+$275K	0.04%	190
2018 Q2	–	Sell	-3,370	Closed	-$254K	–	444
2018 Q1	$254K	Sell	3,370 -62,580	-95%	-$4.97M	0.02%	257
2017 Q4	$4.72M	Buy	65,950 +20,001	+44%	+$1.52M	0.29%	47
2017 Q3	$3.72M	Buy	45,949 +39,203	+581%	+$3M	0.44%	47
2017 Q2	$477K	Buy	6,746 +3,006	+80%	+$200K	0.05%	237
2017 Q1	$254K	Sell	3,740 -9,080	-71%	-$638K	0.03%	268
2016 Q4	$918K	Buy	12,820 +8,750	+215%	+$650K	0.06%	160
2016 Q3	$322K	Buy	+4,070	New	+$331K	0.01%	227
2016 Q2	–	Sell	-7,584	Closed	-$697K	–	551
2016 Q1	$697K	Sell	7,584 -184,459	-96%	-$16.6M	0.07%	161
2015 Q4	$19.4M	Buy	192,043 +41,569	+28%	+$4.33M	1.55%	8
2015 Q3	$14.8M	Buy	150,474 +80,932	+116%	+$8.99M	0.9%	18
2015 Q2	$8.14M	Sell	69,542 -151,790	-69%	-$16.6M	0.5%	40
2015 Q1	$21.7M	Buy	221,332 +53,296	+32%	+$5.41M	1.99%	10
2014 Q4	$15.8M	Buy	168,036 +25,299	+18%	+$2.62M	0.95%	17
2014 Q3	$15.2M	Buy	+142,737	New	+$14M	0.83%	21
2014 Q2	–	Sell	-3,429	Closed	-$200K	–	737
2014 Q1	$200K	Buy	+3,429	New	+$269K	0.01%	423
2013 Q3	–	Sell	-4,533	Closed	-$200K	–	472
2013 Q2	$200K	Buy	+4,533	New	+$236K	0.02%	432

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bluefin Capital Management's GILD Position: Q1 2026 in Review

Bluefin Capital Management sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 7,900 shares — an estimated $970K sold.

Bluefin Capital Management first reported a position in GILD in Q2 2013 and held it in 32 quarters. The position peaked at $21.7M in Q1 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Bluefin Capital Management reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Bluefin Capital Management sold 7,900 Gilead Sciences shares in Q1 2026, an estimated $970K.
Bluefin Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 32 quarters.
Bluefin Capital Management's Gilead Sciences position peaked at $21.7M in Q1 2015.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.